Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 16/20 | 0.78 |
| ▸ | PDE4A | P27815 | 10/20 | 0.78 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.78 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.78 |
| ▸ | PDE5A | O76074 | 4/20 | 0.56 |
| ▸ | PDE1A | P54750 | 2/20 | 0.56 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.56 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13524375 | 0.91 | PDE4D (0.76) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL13652966 | 0.89 | PDE4D (0.72) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| Piclamilast SCHEMBL26573 | 0.88 | PDE4D (1.00) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL7335911 | 0.87 | PDE4D (0.98) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL7332164 | 0.85 | PDE4D (0.74) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL14456041 | 0.84 | PDE4D (0.88) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL7359687 | 0.83 | PDE4D (0.86) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL7335169 | 0.83 | PDE4D (0.83) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL7338641 | 0.83 | PDE4D (1.00) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL7334025 | 0.82 | PDE4D (0.82) | PDE4DPDE4APDE4BPDE4CPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | CANNIZZARO CARINA | 2009-10-01 | — | — | US | disclosed |
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | CANNIZZARO CARINA | 2009-10-01 | — | — | US | disclosed |
| US-7432261-B2 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432261-B2 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | PHOSPHO1, TNF, PTGES | PDE4D 1243/4885PDE4A 432/4885PDE4B 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.